Top Page
Atomo Diagnostics Ltd.
(Sydney:AT1)
Atomo Diagnostics Ltd. (AT1) vs. S&P 500 (SPY)
Atomo Diagnostics Ltd. Business Overview & Revenue Model
Atomo Diagnostics Ltd. Financial Statement Overview
| Breakdown | |||||
| TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 4.22M | 4.09M | 2.54M | 12.34M | 6.72M | 5.37M | Gross Profit |
| 1.48M | 1.44M | -6.08M | -1.85M | -1.71M | -464.83K | EBIT |
| -3.90M | -7.16M | -10.04M | -8.11M | -6.18M | -3.58M | EBITDA |
| -4.95M | -5.42M | -9.25M | -4.72M | -4.70M | -4.05M | Net Income Common Stockholders |
| -6.45M | -6.85M | -9.96M | -5.71M | -6.02M | -9.22M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 6.51M | 3.69M | 6.47M | 12.97M | 17.95M | 27.10M | Total Assets |
| 14.93M | 11.38M | 16.47M | 26.62M | 32.24M | 36.10M | Total Debt |
| 171.46K | 84.67K | 254.88K | 340.81K | 67.59K | 55.54K | Net Debt |
| -6.34M | -3.60M | -6.22M | -12.63M | -17.88M | -27.05M | Total Liabilities |
| 1.23M | 1.29M | 1.68M | 1.81M | 2.15M | 1.62M | Stockholders Equity |
| 13.70M | 10.08M | 14.79M | 24.81M | 30.09M | 34.48M |
| Cash Flow | Free Cash Flow | ||||
| -3.59M | -4.70M | -6.25M | -5.11M | -10.12M | -8.26M | Operating Cash Flow |
| -3.53M | -4.69M | -5.85M | -2.81M | -4.23M | -6.26M | Investing Cash Flow |
| -54.49K | -16.08K | -401.28K | -2.31M | -5.90M | -1.99M | Financing Cash Flow |
| -191.39K | 1.87M | -170.75K | 17.61K | 997.37K | 33.61M |
Atomo Diagnostics Ltd. Technical Analysis
Atomo Diagnostics Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | AU$56.52B | 27.97 | 25.23% | 0.82% | 10.54% | 38.69% | |
76 Outperform | $1.42B | 86.45 | 9.23% | ― | 10.79% | 5.20% | |
64 Neutral | $116.12B | 27.87 | 15.38% | 1.91% | 8.00% | 9.09% | |
63 Neutral | $8.64B | 166.49 | 14.52% | ― | 55.85% | 893.42% | |
52 Neutral | $5.04B | 3.15 | -44.58% | 2.85% | 16.08% | -0.27% | |
48 Neutral | AU$340.93M | ― | -0.87% | 5.83% | 14.24% | -109.59% | |
39 Underperform | AU$11.66M | ― | -61.15% | ― | 35.63% | 18.55% |
Atomo Diagnostics Ltd. Corporate Events
Atomo Diagnostics Ltd. has announced a change in the substantial holding of its voting shares. GZ Family Holdings Pty Ltd and GZ Super Investments Pty Ltd have increased their voting power in Atomo Diagnostics, indicating a strategic consolidation of control. This change reflects a significant shift in the company’s shareholder structure, potentially impacting its governance and strategic direction.
Atomo Diagnostics Limited announced the resignation of Paul Kasian from its board of directors, effective May 2, 2025. This change in leadership may influence the company’s strategic direction and stakeholder relations, as Kasian held significant shares through Yongala Investments Pty Ltd, indicating his substantial involvement in the company’s operations.
Atomo Diagnostics Ltd. has announced the appointment of Anthony May as a director, effective from May 2, 2025. This appointment is part of the company’s ongoing efforts to strengthen its leadership team, which could impact its strategic direction and operational effectiveness in the diagnostics industry.
Atomo Diagnostics Limited announced the issuance of 46,929,731 fully paid ordinary shares to new and existing investors at an issue price of $0.0185 per share. This move, executed without disclosure under the Corporations Act, aims to strengthen the company’s financial position and support its operations in the competitive global diagnostic market. The announcement confirms Atomo’s compliance with relevant legal provisions and assures stakeholders of its transparency and adherence to regulatory standards.
Atomo Diagnostics Ltd. has announced the quotation of 46,929,731 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of May 5, 2025. This move is part of a previously announced transaction, potentially enhancing the company’s market presence and providing opportunities for stakeholders to engage with its growth strategy.
Atomo Diagnostics Ltd. has updated its previous announcement regarding the issuance of securities, specifically adjusting the number of securities to be issued in Tranche 1 and Tranche 2 of the placement. This adjustment is crucial for stakeholders as it corrects the total amount of securities being issued, impacting the company’s financial strategy and market positioning.
Atomo Diagnostics Ltd. has reported significant growth in its HIV Self-Test business, highlighted by a $230k order for the national scale-up of the CONNECT Programme in Australia and a product launch in New Zealand through Chemist Warehouse. The company also secured an exclusive license for a novel syphilis test, supported by a $2.44 million grant from the Commonwealth Government, which will aid in further analytical testing and commercial discussions.
Atomo Diagnostics Ltd. announced a proposed issue of securities through a securities purchase plan and a placement, aiming to issue a total of 166,486,487 new securities. This move is expected to enhance the company’s capital structure, potentially strengthening its market position and providing additional resources to support its operational and strategic initiatives.
Atomo Diagnostics Limited has successfully completed a capital raise of up to $3.1 million through a share placement and share purchase plan, supported by existing shareholders. This capital raise aims to support the company’s general working capital needs and involves issuing new shares and options, with a board restructure and operational review expected to result in further cost savings and strategic alignment.
Atomo Diagnostics Limited announced that it will release its Q3 FY25 results on April 24, 2025, with a briefing webinar scheduled for April 30, 2025. This announcement is part of Atomo’s ongoing efforts to engage with analysts and investors, reflecting its commitment to transparency and stakeholder communication. The release of these results and the subsequent webinar could provide insights into the company’s financial health and strategic direction, potentially impacting its market positioning and stakeholder confidence.
Atomo Diagnostics Ltd. has announced a change in the director’s interest, specifically involving John Kelly, who is a controller of Dalraida Holdings Pty Ltd. The change involved the expiry of 666,666 unquoted options without exercise as of April 14, 2025. This adjustment in the director’s interest does not involve any acquisition or disposal of shares, indicating a neutral impact on the company’s operations and market positioning.
Atomo Diagnostics Limited has requested a trading halt on its securities on the Australian Securities Exchange, pending a significant announcement related to a capital raising initiative. This move is aimed at managing the company’s continuous disclosure obligations and is expected to impact the company’s financial strategy and market positioning.
Atomo Diagnostics announced the national expansion of the CONNECT Programme, which will provide free HIV self-tests through vending machines across Australia, funded by the Federal Government. This initiative, supported by an initial order from Thorne Harbour Health, represents a significant advancement in public health efforts to increase access to HIV self-testing. Additionally, Atomo has launched its HIV Self-Test in New Zealand through Chemist Warehouse, marking its entry into the country’s largest retail pharmacy chain. These developments highlight Atomo’s growing influence in the HIV testing market and its commitment to expanding international market access.
Atomo Diagnostics Ltd. has announced an immediate suspension of its securities from quotation on the ASX to prevent a disorderly or uninformed market. This follows a trading halt earlier in the day pending a market-sensitive announcement, which the company has since deemed non-sensitive. The suspension will remain until the announcement is released and conditions are met for reinstatement, potentially impacting stakeholder confidence and market operations.
Atomo Diagnostics Ltd. has released its H1 FY2025 results presentation, emphasizing that the information provided is for general purposes and should not be solely relied upon for investment decisions. The presentation includes disclaimers regarding the accuracy and completeness of the information, and highlights the potential risks and uncertainties associated with forward-looking statements, indicating that actual results may differ from expectations.
Atomo Diagnostics Limited reported a 7% increase in revenues to AUD 2,052,476 for the half-year ended December 31, 2024, while also reducing its loss from ordinary activities after tax by 12% to AUD 2,758,734. Despite the improvements in revenue and reduced losses, the company did not declare any dividends, and its net tangible assets per ordinary security decreased from 1.25 AUD cents to 0.87 AUD cents, indicating a potential area of concern for stakeholders.
Atomo Diagnostics Limited announced the release of its H1 FY25 results, scheduled for 28 February 2025, with a subsequent results briefing webinar for analysts and investors on 3 March 2025. This announcement signifies Atomo’s ongoing commitment to transparency and engagement with stakeholders, potentially impacting its market position and investor relations positively.